Latest Filana Therapeutics News & Updates

See the latest news and media coverage for Filana Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Filana Therapeutics

Clinical-stage biotechnology company developing treatments for central nervous system disorders

filanatx.com

Headquarters: Austin, United States
Company type: Public company
Number of employees: 10–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Filana Therapeutics

In short: Filana Therapeutics received FDA clearance to advance simufilam into a Phase 2a trial for TSC-related epilepsy.

Company announcements

September 22 Filana Therapeutics

Filana Therapeutics advances simufilam trial after FDA lifts hold

The clearance enables a Phase 2a study in TSC-related epilepsy, with patient screening expected to begin by the first quarter of 2027.

July 29 Filana Therapeutics

Filana Therapeutics reports Q2 2026 financial results

The company posts an $8.6 million net loss and holds $82.7 million in cash while paying a $31.25 million litigation settlement to resolve securities claims.

March 10 Filana Therapeutics

Cassava Sciences announces rebranding to Filana Therapeutics

The company changes its ticker to FLNA and shifts focus to developing filamin A modulators for CNS disorders like TSC-related epilepsy.

January 13 Filana Therapeutics

Cassava announces Phase 3 simufilam results in Alzheimer's journal

Trials missed primary endpoints but showed exploratory insights. Cassava stopped the program to focus on epilepsy.

Media coverage

September 22 Yahoo Finance

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027Filana has engaged a leading clinical research organization, has...

September 19 The Globe and Mail

Filana Therapeutics Receives Nasdaq Minimum Bid Price Notice

Detailed price information for Filana Therapeutics Inc (FLNA-Q) from The Globe and Mail including charting and trades.

July 29 Finanznachrichten

Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies...

March 10 Finanznachrichten

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics...

Never miss news about Filana Therapeutics

Track Filana Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Filana Therapeutics competitors & trending companies

Browse news for competitors to Filana Therapeutics and other trending companies.